Interactive Session - Hormone Therapy in Early Menopause

Presenters

Hormone Therapy in Early Menopause

Needs Assessment and Description
Kronos Early Estrogen Prevention Study (KEEPS) is a multicenter, randomized, controlled trial of menopausal hormone therapy (MHT) that was designed to tackle headon the timing hypothesis. The primary goal of KEEPS was to assess cardiovascular implications of estrogen when initiated early in the process of menopause in otherwise healthy women within 3 years of their last menstrual period. The neurocognitive ancillary study to KEEPS focused on the study of effects of menopausal hormones on neurocognitive parameters in early postmenopausal women. KEEPS investigators will share the observed effects of menopausal hormones on cardiovascular and neurocognitive endpoints in participants who completed a 4-year randomized, controlled trial of estrogen (0.45 mg of conjugated equine estrogens, 50 mg weekly transdermal estradiol) both in combination with cyclic oral, micronized progesterone (200 mg for 12 days each month) and placebo. This live course for womens' healthcare providers and trainees will offer a critical update of evidence and will provide evidencebased recommendations for optimizing care for early menopausal women.

Learning Objectives
At the conclusion of this session, participants should be able to: 

1. Describe the implications of menopausal hormone use for cardiovascular endpoints in early menopausal women. 
2. Explain effects of menopausal hormones on cognitive parameters and mood in early menopausal women.
3. Discuss risk versus benefit of menopausal hormone therapy in early menopausal women.

ACGME Competency
Patient Care

TEST QUESTION:
A 50-year-old Caucasian woman presents for consultation for bothersome vasomotor symptoms, disturbed sleep and increasing forgetfulness. Her last menstrual period was 13 months prior to this visit. Her medical history is unremarkable. Her family history is significant for hypertension (mother became hypertensive at age 55) and for dementia (maternal grandmother was diagnosed with dementia at age 70). After participating in this session, in my practice I will counsel this patient: 

1. Regarding risks versus benefits of menopausal hormone therapy, especially cardiovascular and neurocognitive concerns. 
2. That hormone therapy should be avoided. 
3. That she should consider undergoing hysterectomy. 
4. Not applicable to my area of practice.